Your email has been successfully added to our mailing list.

×
0.000143034232859737 -0.000476780776199077 -0.000524458853818944 -0.00109659578525789 -0.000619815009058813 -0.000572136931438946 -0.00786688280728524 -0.00829598550586445
Stock impact report

Citius Oncology rises after U.S. launch of Lymphir as a cancer treatment [Seeking Alpha]

Cardinal Health, Inc. (CAH) 
Last cardinal health, inc. earnings: 2/6 06:55 am Check Earnings Report
US:NYSE Investor Relations: ir.cardinalhealth.com/home
Company Research Source: Seeking Alpha
The drug was approved in August by the FDA. Under a deal between the company and Cardinal Health, the latter is an authorized distributor for the company, providing pharmaceutical distribution services. The stock is up about 19.7% More on Citius Oncology Citius Oncology prices $9 million offering; shares down over 5% Seeking Alpha's Quant Rating on Citius Oncology Historical earnings data for Citius Oncology Financial information for Citius Oncology Show less Read more
Impact Snapshot
Event Time:
CAH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for CAH alerts
Opt-in for
CAH alerts

from News Quantified
Opt-in for
CAH alerts

from News Quantified